Our rationale is that treatment with an antibiotic that unnecessarily targets ESBL-PE (e.g. a fourth-generation cephalosporin, a carbapenem or inclusion of a beta lactamase inhibitor) would do less harm than erroneous treatment with an ineffective antibiotic during a moderate to severe infection. This evidence concerns the gene LACTB and infection.